Jilin Aodong Pharmaceutical Group Co., Ltd.
000623
Rankning i aktier
#4830
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally... Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally focusing on the production and distribution of a broad spectrum of pharmaceutical goods. Its product line encompasses various drug forms like oral liquids, injections, capsules, granules, pills, and tablets, as well as traditional Chinese herbal medicines, powders, syrups, and spirits. The company also produces specialized medicinal products, including enzymes, biochemical drugs, and plant-based chemical medicines. In addition to its core pharmaceutical activities, Jilin Aodong diversifies its operations across several other sectors. These include highway construction and toll management, animal husbandry, the creation of specialty chemicals, and the provision of heat and water. The company further engages in the wholesale, retail, and distribution of medicines, packaging design and printing, the manufacturing of medicinal packaging materials, and delivers information consulting and advertising design solutions. Founded in 1957, its corporate headquarters are situated in Dunhua, China.
Aktiekurs
$2.52
Marknadsvärde
$3.01B
Förändring (1 dag)
-1.18%
Förändring (1 år)
-11.71%
Land
CN
Handel Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Kategori
Healthcare
Intäkter för Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Intäkter i Jun 2026 TTM: $324.58M
Enligt Jilin Aodong Pharmaceutical Group Co., Ltd. senaste finansiella rapporter är företagets nuvarande intäkter (TTM) $324.58M. År 2024 hade företaget intäkter på $357.66M en minskning jämfört med intäkterna år 2023, som var $487.26M. Intäkter är det totala belopp som ett företag genererar från försäljning av varor eller tjänster. Till skillnad från vinst dras inga kostnader av.
Intäktshistorik för Jilin Aodong Pharmaceutical Group Co., Ltd. från 2000 till 2026
Intäkter vid slutet av varje år
| År | Intäkter | Ändra |
|---|---|---|
| 2026 (TTM) | $324.58M | -2.75% |
| 2025 | $333.77M | -6.68% |
| 2024 | $357.66M | -26.60% |
| 2023 | $487.26M | 17.18% |
| 2022 | $415.81M | 14.72% |
| 2021 | $362.46M | 5.16% |
| 2020 | $344.67M | -22.29% |
| 2019 | $443.52M | -8.22% |
| 2018 | $483.25M | 5.62% |
| 2017 | $457.53M | 16.07% |
| 2016 | $394.17M | 9.63% |
| 2015 | $359.54M | -0.59% |
| 2014 | $361.66M | 12.10% |
| 2013 | $322.61M | 39.17% |
| 2012 | $231.80M | 27.60% |
| 2011 | $181.66M | 7.70% |
| 2010 | $168.67M | 12.29% |
| 2009 | $150.21M | 10.47% |
| 2008 | $135.97M | 17.47% |
| 2007 | $115.75M | 17.31% |
| 2006 | $98.67M | 3.79% |
| 2005 | $95.06M | -4.15% |
| 2004 | $99.18M | 21.83% |
| 2003 | $81.41M | 17.43% |
| 2002 | $69.33M | 28.70% |
| 2001 | $53.87M | 41.79% |
| 2000 | $37.99M | 0.00% |
Intäkter för liknande företag eller konkurrenter
| Företag | Intäkter | Intäktsdifferens | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 1,936.98% |
IN
|
